Compare GE Aerospace (GE) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GE Aerospace vs Tango Therapeutics Inc. — how do they compare? GE Aerospace trades at $308.69 (market cap $318.55B), while Tango Therapeutics Inc. trades at $22.5 (market cap $3.74B). The key difference: GE Aerospace is far larger — about 85.2× Tango Therapeutics Inc.'s market cap, and GE Aerospace pays a 0.61% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold GE Aerospace for 111 Days and Tango Therapeutics Inc. for 0 Days on average.
| GE | TNGX | |
|---|---|---|
Market Cap | $318.55B | $3.74B |
Volume | 3,302,020 | 3,438,781 |
Sector | Industrials | Health |
52-Week High | $381.22 | $32.90 |
52-Week Low | $273.25 | $7.50 |
Typical Hold Time | 111 Days | 0 Days |
Enterprise Value | $328.36B | $2.76B |
Dividend Yield | 0.61% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GE Aerospace trades at $307.63, down 0.33% with a bearish technical signal despite strong fundamentals. The company has beaten earnings estimates for three consecutive quarters, achieving 48.79% ROE and 17.72% net margins. Recent news highlights a $12 billion acquisition of Consolidated Precision Products to address supply chain bottlenecks, while analysts maintain a strong buy consensus with a $409.60 price target representing 33% upside potential.
GE presents a compelling investment case with robust earnings momentum and strategic acquisitions, though technical weakness and high valuation multiples (P/E 36.28) warrant caution. The stock faces near-term pressure from cost concerns and regulatory scrutiny of the CPP deal, but strong defense demand and shareholder returns support long-term growth prospects.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About GE Aerospace
General Electric Company is a globally diversified technology and financial services company. The Company's products and services include aircraft engines, power generation, water processing, and household appliances to medical imaging, business and consumer financing, and industrial products.
Read more on GE →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
